Book in one sentence: A UK GP strips the misinformation out of menopause and replaces it with the actual evidence: hormones, HRT, symptoms, metabolism, and all.
- What Is The Science of Menopause About?
- What Does Menopause Actually Do to Your Metabolism?
- Is HRT Really as Dangerous as Everyone Says?
- What About the Symptoms Nobody Talks About?
- Is The Science of Menopause Worth Reading?
- Books Like The Science of Menopause
What Is The Science of Menopause About?
You ask your doctor about HRT and she says she’s “not really comfortable with it.” You search online and get 457 million results. You find a Facebook group and come away more confused than before. This is the information environment most women are navigating when their bodies start behaving in ways they don’t recognize.
Dr. Philippa Kaye is a UK GP (general practitioner) and the author of nine books on women’s health. She wrote this one because her consulting room was full of women who didn’t understand what was happening to them, assumed their symptoms were just aging, or were refusing treatments because of clinical trial data from 2002 that was badly misapplied for two decades. The book is structured as a Q&A, so you can open it to “Why am I gaining weight?” or “What is genitourinary syndrome?” and get a direct clinical answer. You can also read it front to back and build a coherent picture of the whole transition.
At 224 pages, it reads more like a medical briefing than a book. Dense, well-organized, no filler. The tone is what you’d want from a doctor who actually has 30 minutes to talk to you: clear, evidence-grounded, and without an agenda beyond helping you make informed decisions.
What Does Menopause Actually Do to Your Metabolism?
This is the section that matters most if weight and eating have been part of your story.
The average adult gains 1 to 1.5 pounds per year from early adulthood through middle age. That’s not a perimenopause problem specifically. It’s what happens when muscle mass gradually declines with age and nobody replaces it. Muscle burns more calories at rest than fat does, so losing muscle without adding it back creates a slow caloric gap even when nothing else changes. Perimenopause accelerates this process.
Estrogen also controls where fat gets deposited. As levels fall, fat shifts from the hips and thighs toward the abdomen (visceral fat), and the body simultaneously tries to produce an alternative form of estrogen called estrone from adipose tissue. Visceral fat carries higher metabolic and cardiovascular risk than subcutaneous fat. This is why body composition changes in midlife can feel so different from earlier weight gain (same number on the scale, different distribution, different implications).
Kaye’s practical recommendation is strength training twice per week as a specific clinical priority, not a general wellness suggestion. The goal isn’t aesthetics. It’s preserving the metabolic engine that’s been quietly losing mass since your thirties. For anyone whose relationship with food and weight has been complicated, this framing is worth sitting with: the changes aren’t a personal failure, and the lever isn’t less food. It’s more muscle.
“With a lower muscle mass, even if you consume the same amount of food/calories, you will gain weight.” (Philippa Kaye)
Is HRT Really as Dangerous as Everyone Says?
The short answer is: the HRT most women are afraid of is not the HRT being prescribed now.
In the early 2000s, a major US study called the Women’s Health Initiative (WHI) published results suggesting that HRT increased risks of breast cancer and cardiovascular disease. Prescriptions dropped by 50 percent almost overnight. The fear stuck, and it’s still in the room when most women have this conversation with their doctors today.
Here’s what the coverage got wrong. The average participant in that study was 63 years old. These were not perimenopausal women in their mid-forties. The study also used oral synthetic estrogen and synthetic progestins, formulations that look nothing like what evidence-based practitioners currently prescribe. Kaye walks through the key distinctions:
- Transdermal estrogen (gel, patch, or spray) bypasses the liver and carries no increased risk of blood clots or stroke. Oral estrogen does carry that risk. Delivery route matters clinically.
- Micronized progesterone (sometimes called Utrogestan or Gepretix) is body-identical and plant-derived. It carries a much lower breast cancer signal than the synthetic progestins studied in the WHI.
- Timing matters. HRT started within 10 years of menopause onset may be cardioprotective. Starting much later, in women who already have established cardiovascular disease, carries a different risk profile.
The WHI findings were real for that population, using those formulations, at those ages. The harm was in applying those conclusions to a completely different group. Kaye doesn’t demonize the researchers. She frames this as a clinical literacy problem, one that has cost women years of unnecessary suffering, bone fractures, and preventable cardiovascular events. Undertreated menopause is its own health crisis, and she makes that case with specifics.
For women who can’t or don’t want to use HRT, the non-hormonal options get the same rigorous treatment. Fezolinetant (brand name Veoza, FDA-approved 2023) is the first non-hormonal prescription drug specifically targeting the mechanism of hot flashes. SSRIs and SNRIs reduce hot flash frequency by 30 to 60 percent. CBT is clinically validated for hot flashes, insomnia, anxiety, and depression. The book rates each option by evidence quality, which is more useful than a list.
What About the Symptoms Nobody Talks About?
Hot flashes get the most airtime, but Kaye explains why they happen in a way most books skip. The hypothalamus keeps body temperature within a narrow range. Estrogen normally moderates a peptide called neurokinin B (NKB). As estrogen falls, NKB overstimulates the thermoregulatory center via NK3 receptors, and the brain reads a temperature emergency that isn’t happening. The body launches its heat-dissipation response: vasodilation, flushing, sweating. Core body temperature doesn’t actually rise. You’re cooling something that isn’t hot. Understanding this mechanism explains why fezolinetant works without hormones: it blocks the NK3 receptor directly.
Mood symptoms are consistently misidentified. Perimenopausal women are 40 percent more likely to be diagnosed with depression than premenopausal women, and mood changes (anxiety, irritability, low mood, brain fog) often show up before hot flashes do. Women in their mid-forties get put on antidepressants with nobody connecting the symptoms to hormonal fluctuation. Estrogen supports serotonin synthesis and receptor sensitivity; progesterone acts on GABA receptors. As both hormones decline and swing erratically (Kaye’s phrase: “a roller-coaster”), the neurochemical scaffolding for mood stability is progressively removed. HRT can resolve hormonally-driven mood symptoms that antidepressants alone won’t touch.
Genitourinary syndrome of menopause (GSM) is the symptom with the worst visibility gap. It covers vaginal dryness, painful sex, recurrent UTIs, and urinary urgency, and it affects over half of postmenopausal women. Unlike hot flashes, which often ease over time, GSM is progressive without treatment. Vaginal estrogen is the definitive fix: local application, minimal systemic absorption, safe for most women including breast cancer survivors, reduces UTI frequency by more than 50 percent in studies. It takes three to six months for full effect and should be continued long-term because the condition is chronic. Women don’t report it (stigma, or the assumption that sex is just supposed to hurt now), and clinicians often don’t ask. The silence around GSM costs women years of avoidable suffering that is, in most cases, straightforwardly treatable.
Is The Science of Menopause Worth Reading?
Read this if you want one reliable, clinical reference on perimenopause and you’re done wading through wellness influencer content that can’t tell you why hot flashes happen or what micronized progesterone actually is. Kaye treats readers as adults. For anyone who has struggled with weight and wants to understand the metabolic mechanics of this transition (not just “eat less, exercise more”), the muscle mass and fat distribution sections are unusually well-sourced and direct. If you’re on a GLP-1 medication and navigating perimenopause at the same time, the sections on muscle preservation and metabolic rate are directly relevant to how both interventions interact.
Skip it if you want a diet plan, a step-by-step protocol, or extended personal narrative. This is a reference book. The lifestyle chapter is evidence-grounded but concise: it points to what works and why, without building out full programs. Also worth noting: Kaye is a UK GP, so her treatment recommendations follow NICE guidelines, which sometimes differ from US FDA approvals. The distinctions are flagged in the text, but you’ll need to translate some of it.
One caveat: The reader rating reflects the fact that some readers found it too dense or too clinical. That’s accurate. It reads like a thorough GP who won’t waste your appointment. Whether that’s a feature or a bug depends entirely on what you showed up for.
Books Like The Science of Menopause
| Book | Author | Best For |
|---|---|---|
| Menopause Bootcamp | Suzanne Gilberg-Lenz | A warmer, more lifestyle-forward companion to Kaye’s clinical lens |
| The Menopause Brain | Lisa Mosconi | Goes deep on the cognitive and neuroprotective angle Kaye covers briefly |
| The Great Menopause Myth | Kristin Johnson | Functional medicine approach, more integrative, less evidence-rigorous |
| The Power of Hormones | Max Nieuwdorp | Broader hormonal context, useful for understanding the full endocrine picture |
| It’s Your Hormones | Geoffrey Redmond | US-focused, clinical, good for understanding HRT formulation options in more depth |